Literature DB >> 20043079

Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells.

Christoph Dorn1, Thomas S Weiss, Jörg Heilmann, Claus Hellerbrand.   

Abstract

Xanthohumol, the major prenylated chalcone found in hops, is well known to exert anti-cancer effects, but information regarding the impact on hepatocellular carcinoma (HCC) cells and potential adverse effects on non-tumorous hepatocytes is limited. Here, we show that xanthohumol at a concentration of 25 microM induced apoptosis in two HCC cell lines (HepG2 and Huh7). Furthermore, xanthohumol repressed proliferation and migration, as well as TNF induced NF-kappaB activity and interleukin-8 expression in both cell lines at even lower concentrations. In contrast, xanthohumol concentrations up to 100 microM did not affect viability of primary human hepatocytes in vitro. In summary, our data showed that xanthohumol can ameliorate different pro-tumorigenic mechanisms known to promote HCC progression, indicating its potential as promising therapeutic agent that selectively affects cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043079

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

Review 1.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

2.  Chemoprevention against hepatocellular carcinoma.

Authors:  Jun-Ichi Okano; Yuki Fujise; Ryo Abe; Ryu Imamoto; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2011-06-04

3.  Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis.

Authors:  Christoph Dorn; Jörg Heilmann; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

4.  Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells.

Authors:  Selvi Kunnimalaiyaan; Jose Trevino; Susan Tsai; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Mol Cancer Ther       Date:  2015-04-17       Impact factor: 6.261

5.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

Review 6.  Xanthohumol for Human Malignancies: Chemistry, Pharmacokinetics and Molecular Targets.

Authors:  Vancha Harish; Effi Haque; Magdalena Śmiech; Hiroaki Taniguchi; Sarah Jamieson; Devesh Tewari; Anupam Bishayee
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

7.  Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma.

Authors:  Selvi Kunnimalaiyaan; Kevin M Sokolowski; Mariappan Balamurugan; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 8.  The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels.

Authors:  Ralf Weiskirchen; Abdo Mahli; Sabine Weiskirchen; Claus Hellerbrand
Journal:  Front Physiol       Date:  2015-05-06       Impact factor: 4.566

9.  An update on antitumor activity of naturally occurring chalcones.

Authors:  En-Hui Zhang; Ru-Feng Wang; Shu-Zhen Guo; Bin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

10.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol-A Natural Compound Present in Humulus lupulus L.

Authors:  Małgorzata Kłósek; Anna Mertas; Wojciech Król; Dagmara Jaworska; Jan Szymszal; Ewelina Szliszka
Journal:  Int J Mol Sci       Date:  2016-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.